Gregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.
Gregory A. Daniels, MD, PhD, associate clinical professor of medicine, Division of Hematology-Oncology, University of California, San Diego, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies. Daniels references the results of the 2007-2012 PROCLAIM National Registry, which was presented at the 2014 ASCO Annual Meeting.
Read about combining immunotherapies > >
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More